Foghorn Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Foghorn Therapeutics (FHTX).

Price Target Range — 10 Quarters

Analyst Consensus — 10 Analysts

1S.Buy

6Buy

3Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$10Upside to Avg. PT+417.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Wedbush	Robert Driscoll	Downgrade	Outperform→Neutral	$10→$2
Oct 2, 2026	TD Cowen	Yaron Werber	Downgrade	Buy→Hold	—
Oct 2, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$12→$5
Oct 2, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$13→$5
Oct 2, 2026	BTIG	Jeet Mukherjee	Downgrade	Buy→Neutral	—
Mar 12, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$10
Mar 10, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$13
Feb 17, 2026	Jefferies	Amin Makarem	PT Cut	Buy	$14→$12
Dec 18, 2025	BTIG	Jeet Mukherjee	Initiate	Buy	$11
Dec 4, 2025	Stifel	Laura Prendergast	Initiate	Buy	$12
Nov 7, 2025	Guggenheim	Michael Schmidt	Initiate	Buy	$12
May 15, 2025	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$9
Apr 30, 2025	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$9
Apr 30, 2025	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$13
Apr 23, 2025	JMP Securities	Silvan Tuerkcan	Initiate	Market Outperform	$9
Mar 7, 2025	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$13
Jan 30, 2025	B. Riley Securities	Kalpit Patel	Initiate	Buy	$10
Dec 17, 2024	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$20→$13
Dec 16, 2024	Jefferies	Kelly Shi	PT Cut	Buy	$18→$14
Sep 24, 2024	Morgan Stanley	Vikram Purohit	PT Raise	Equal-Weight	$6→$9

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.

Benzinga Newsdesk

PRO
TD Cowen Downgrades Foghorn Therapeutics to Hold

TD Cowen analyst Yaron Werber downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Hold.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

Guggenheim analyst Michael Schmidt maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $12 to $5.

Benzinga Newsdesk

Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday

Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.

Avi Kapoor

This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $13 to $5.

Benzinga Newsdesk

Foghorn Therapeutics Inc

Foghorn Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

PRO
TD Cowen Downgrades Foghorn Therapeutics to Hold

PRO
Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday

This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

PRO
HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

People Also Watch

People Also Watch

Foghorn Therapeutics Inc

Foghorn Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

PROTD Cowen Downgrades Foghorn Therapeutics to Hold

PROGuggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday

This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

PROHC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

People Also Watch

People Also Watch

PRO
Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

PRO
TD Cowen Downgrades Foghorn Therapeutics to Hold

PRO
Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5